Johnson & Johnson (JNJ) Stock Analysis & AI Equity Report

Drug Manufacturers - General USD Explore free reports

Johnson & Johnson (JNJ) overview

Johnson & Johnson (JNJ) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 94,193m and operating profit of USD 25,287m; the year-end share price was 207.63 USD and market capitalisation was USD 499,960m. Johnson & Johnson is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Johnson & Johnson's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 81,544mFY 2025
Share price207.63 USDFY 2025 year end
RevenueUSD 94,193mFY 2025
Operating profitUSD 25,287mFY 2025
Net earningsUSD 26,804mFY 2025
Market capitalisationUSD 499,960mFY 2025 year end

About Johnson & Johnson

Johnson & Johnson develops, manufactures, and sells healthcare products through its Innovative Medicine and MedTech segments. Its medicines address areas including cancer, immune disorders, neuroscience, infectious diseases, and cardiovascular conditions, and are distributed to retailers, wholesalers, hospitals, and healthcare professionals for prescription use. The company also supplies medical technologies through its MedTech business.

Generate the Johnson & Johnson report

Johnson & Johnson is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Johnson & Johnson and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Johnson & Johnson

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.